Growth hormone deficiency (GHD) is diagnosed through stimulation tests that measure how your pituitary gland responds when it’s chemically triggered to release growth hormone. A simple blood draw can’t confirm the diagnosis on its own because growth hormone is released in pulses throughout the day, making a single reading unreliable. Instead, the diagnostic process typically starts with blood work and clinical evaluation, then moves to specialized provocation tests performed in a medical setting.
Why a Standard Blood Test Isn’t Enough
Growth hormone doesn’t circulate at a steady level. Your pituitary gland releases it in bursts, mostly during sleep and exercise, so a random blood sample could easily read near zero even in a perfectly healthy person. This makes a single growth hormone measurement essentially useless for diagnosis.
What doctors can measure from a routine blood draw is IGF-1, a protein your liver produces in response to growth hormone. Because IGF-1 levels remain relatively stable throughout the day, they serve as a proxy for your overall growth hormone activity. A low IGF-1 result strongly suggests GHD, but the test has significant limitations. Studies show its sensitivity ranges from about 68% to 84% depending on the cutoff used, meaning it misses a substantial number of people who actually have the condition. Factors like nutritional status, body weight, the severity of deficiency, and even which lab runs the test can all skew results. For this reason, IGF-1 is used as a screening tool, not a definitive answer.
IGF-1 reference ranges also shift considerably with age. Median values for adults in their early twenties run around 265 ng/mL, while someone in their seventies typically sits closer to 123 ng/mL. Your doctor interprets your result against age-matched norms, and sometimes sex-specific ranges, though recent evidence suggests separate male and female cutoffs aren’t strictly necessary.
Growth Hormone Stimulation Tests
The gold standard for diagnosing GHD is a stimulation test, sometimes called a provocation test. The concept is straightforward: you’re given a substance that should force your pituitary gland to release growth hormone, and your blood is drawn at timed intervals to see how high your levels climb. If your peak growth hormone stays below a specific threshold, that confirms the deficiency.
Several stimulation agents are used, each with its own protocol and cutoff values:
- Insulin tolerance test (ITT): Considered the reference standard. Insulin is injected to lower your blood sugar, which normally triggers a strong growth hormone response. A peak GH of 5 mcg/L or below is diagnostic in adults. Because it involves induced low blood sugar, it requires close medical monitoring and isn’t suitable for people with seizure disorders or heart conditions.
- Glucagon stimulation test: An alternative when the insulin test isn’t safe. Glucagon is injected, and blood is drawn over several hours. The diagnostic cutoff is 3 mcg/L or below, though for people with a BMI over 25, a stricter cutoff of 1 mcg/L may be used.
- Macimorelin test: The newest option, FDA-approved in 2017. Unlike the others, it’s taken by mouth rather than injected. Blood samples are drawn at 30, 45, 60, and 90 minutes. A peak GH of 2.8 mcg/L or below confirms deficiency.
Other agents like clonidine and levodopa are sometimes used, particularly in children, with cutoffs generally around 3 mcg/L.
How Testing Differs for Children and Adults
In children, the threshold for concern is typically higher. A peak growth hormone response below 10 mcg/L on a stimulation test is the traditional cutoff, though some guidelines use lower thresholds depending on the specific test. The key difference is that children are generally required to fail two separate stimulation tests using different agents before a diagnosis is confirmed. This two-test rule exists because individual stimulation tests can produce false positives at a surprisingly high rate, and misdiagnosis means years of unnecessary daily injections.
Adults usually need only one failed stimulation test, provided their clinical picture fits. Current guidelines emphasize that stimulation testing in adults should only happen when there’s a genuine intent to treat the deficiency. If someone has a known pituitary condition plus deficiencies in three or more other pituitary hormones and a low IGF-1, some guidelines allow skipping the stimulation test entirely since the diagnosis is already highly likely.
What to Expect During the Test
Stimulation tests are performed in a clinic or hospital, typically in the morning. You’ll need to fast for 8 to 10 hours beforehand, though you can take your regular morning medications with water. The test itself involves an IV line for blood draws and, for most tests, an injection of the stimulating agent. You’ll then sit or lie down while blood samples are collected at set intervals over one to two hours.
The macimorelin test is the most patient-friendly option. You drink a dissolved solution within 30 seconds, then have blood drawn four times over 90 minutes. No IV medications, no induced low blood sugar. In clinical trials comparing it to the insulin tolerance test, it showed strong agreement with the traditional method: at a cutoff of 5.1 mcg/L, sensitivity reached 92% and specificity hit 96%.
The insulin tolerance test is the most physically uncomfortable. Your blood sugar drops deliberately, which can cause sweating, dizziness, and hunger. Medical staff monitor you closely, and glucose is available immediately if symptoms become severe. People who are malnourished or haven’t eaten in more than 48 hours should not undergo the glucagon test, and similar precautions apply to the ITT.
The Role of Brain Imaging
An MRI of the pituitary gland is a standard part of the diagnostic workup, though it doesn’t replace stimulation testing. Imaging can reveal structural problems that explain why the gland isn’t producing enough growth hormone. Doctors look for a small or absent anterior pituitary, a thin or missing pituitary stalk, and an ectopic posterior pituitary (meaning the back portion of the gland sits in the wrong location).
In a study of 129 children with confirmed GHD, MRI findings ranged from completely normal anatomy to a fully absent pituitary with no visible stalk. Children with multiple pituitary hormone deficiencies were far more likely to show dramatic structural abnormalities: over 36% had a small or absent anterior pituitary combined with an ectopic posterior pituitary, compared to about 4% of those with isolated growth hormone deficiency. A normal MRI doesn’t rule out GHD, but finding clear structural abnormalities strengthens the diagnosis and can help predict whether the deficiency is permanent or might resolve over time.
Why Cutoffs Depend on Body Weight
Body composition significantly affects growth hormone response. People with higher BMIs naturally produce less growth hormone during stimulation tests, which means using the same cutoff for everyone would over-diagnose GHD in heavier individuals. For the GHRH-arginine test, the cutoffs ranged from 11 mcg/L for people with a BMI under 25 down to 4 mcg/L for those with a BMI of 30 or above. The glucagon test follows a similar pattern, with recent guidelines recommending a cutoff of 1 mcg/L rather than 3 mcg/L for people who are overweight or obese.
This is one reason your doctor considers the full clinical picture rather than relying on a single number. Your symptoms, growth pattern (in children), other hormone levels, MRI findings, and any history of pituitary disease or head injury all factor into the final diagnosis.